MIST

Milestone Pharmaceuticals Inc.

2.99 USD

Last updated Dec 10, 17:58 UTC

Yesterday HIGH

$3.17

Yesterday LOW

$2.82

52w HIGH

$4.88

52w LOW

$2.12

EPS

-0.35

PE

-8.54

Next Earnings

Mar 27, 2024

Overview News Government Trades

Milestone Pharmaceuticals Inc. stock is up 2.75% since 30 days ago. The next earnings date is Mar 27, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 20% of the previous 4 December’s closed higher than November.

Milestone Pharmaceuticals Inc. focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada.

Stock Exchange

NASDAQ

Sector

Manufacturing

Industry

Pharmaceutical Products

Headquarters

-

Website

milestonepharma.com

richadhand@benzinga.com

Thu Mar 30, 2023

HC Wainwright & Co. Reiterates Buy on Milestone Pharmaceuticals, Maintains $25 Price Target

HC Wainwright & Co. analyst Patrick Trucchio reiterates Milestone Pharmaceuticals (NASDAQ:MIST) with a Buy and maintains $25 price target.
Benzinga Newsdesk

Wed Mar 29, 2023

Milestone Pharmaceuticals Q4 EPS $(0.31) Beats $(0.33) Estimate

Milestone Pharmaceuticals (NASDAQ:MIST) reported quarterly losses of $(0.31) per share which beat the analyst consensus estimate of $(0.33) by 6.06 percent. This is a 22.5 percent increase over losses of $(0.40) per
Lisa Levin

Tue Mar 28, 2023

Why Alibaba Shares Are Trading Higher By Over 8%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

Gainers
Benzinga Newsdesk

Tue Mar 28, 2023

Milestone Pharmaceuticals Announced A $125M Strategic Funding With An Existing Shareholder. Proceeds From This Tailored Financing, Together With $64.6M Of Cash Balance As Of December 31, 2022, Are Expected To Fund Operations Into Mid-2025

The strategic financing was anchored by RTW's purchase of $50 million in convertible notes, as well as a commitment of $75 million in non-dilutive royalty funding, which, together, the Company
richadhand@benzinga.com

Thu Mar 9, 2023

HC Wainwright & Co. Reiterates Buy on Milestone Pharmaceuticals, Maintains $25 Price Target

HC Wainwright & Co. analyst Patrick Trucchio reiterates Milestone Pharmaceuticals (NASDAQ:MIST) with a Buy and maintains $25 price target.
Benzinga Newsdesk

Mon Mar 6, 2023

Milestone Pharmaceuticals Progresses Clinical and Regulatory Activities for Etripamil in Patients with Paroxysmal Supraventricular Tachycardia

Both the NODE-303 and RAPID-extension studies are complete Following FDA feedback, Etripamil NDA is on-track for submission in the third quarter of 2023 Potential to be the first fast-acting,
Benzinga Insights

Fri Feb 24, 2023

Stocks That Hit 52-Week Lows On Friday

On Friday, 135 companies reached new 52-week lows.
Benzinga Insights

Mon Dec 19, 2022

Stocks That Hit 52-Week Lows On Monday

On Monday, 297 companies reached new 52-week lows.
Benzinga Insights

Mon Dec 12, 2022

Stocks That Hit 52-Week Lows On Monday

Monday saw 196 companies set new 52-week lows.
Benzinga Insights

Mon Dec 5, 2022

12 Health Care Stocks Moving In Monday's After-Market Session